Rubius Therapeutics Inc., of Cambridge, Mass., said it closed its IPO of 12.05 million shares of common stock at a public offering price of $23 per share. The total includes the exercise in full by the underwriters of their option to purchase up to 1.57 million additional shares. The gross proceeds from the offering were $277.3 million. The shares are now trading on Nasdaq under the ticker RUBY.